INTRODUCTION AND OBJECTIVES: Management of castration-resistant prostate cancer (CPRC) remains challenging due to the inevitable emergence of resistance to treatments including radiotherapy (RT) and chemotherapy (CT). We previously reported that zoledronic acid (ZOL) clinically potentiates the antitumor effects of RT in patients with renal cell carcinoma (Kijima et al, BJU Int 2009) and that this radiosensitization could occur through the osteoclast-independent inhibition of signal transducer and activator of transcription 1 (STAT1) (Kijima et al, PLoS One 2013). As the association between STAT1 overexpression and treatment resistance has been reported in several cancers, we investigated whether STAT1 is associated with resistance to RT and CT in CRPC cells and whether ZOL could overcome this resistance by downregulating STAT1.
INTRODUCTION AND OBJECTIVES: Modulating the activity of eukaryotic elongation factor 2 kinase (eEF2K) has been suggested to regulate protein elongation to block autophagy in the tumor microenvironment. Among inhibitors of eEF2K, one would also inhibit VPS34, a class III phosphatidylinositol-3 kinase, and abrogate autophage flux to impair the survival escape mechanism. We tested the eEF2K and VPS 34 inhibitors from Janssen alone or in combination with anti-androgens for their effects on proliferation of prostate cancer cell lines, especially some castration resistant PC (CRPC) lines.
METHODS: Cell proliferation was assessed with various concentrations of the EF2K or VPS34 inhibitor on CRPC lines using WST-1 viability assay. Effect of combinations of EF2K or VPS34 inhibitor with anti-androgens abiraterone (Abi) or enzalutamide (Enza) on drugresistant CRPC cells was further explored. Western blot analysis was performed to examine the response of key autophagic molecules, androgen receptor (AR) and variant. Real time RT-PCR (RT-qPCR) was used to elucidate the effect of EF2K or VPS34 inhibitor alone or together with anti-androgens on AR, AR variant and their downstream molecules.
RESULTS: EF2K and VPS34 inhibitors suppressed CRPC cell growth in a dose-response manner with IC50 ranging from 1 to 5 mM. These inhibitors displayed synergy with Abi and Enza against drugresistant CRPC cells; especially on the pair of enza + EF2K inhibitor with p ¼ 0.02 for significant difference when compared to enza or EF2K inhibitor alone. To our surprise, no significant autophagy was induced by these two inhibitors according to the autophagy markers detected by Western blots. VPS34 inhibitor alone and when combined with Abi and Enza showed AR/variant degrading ability. This downregulation was at the expression level with significant change of AR and V7, together with their transactivation markers PSA, TMPRS2, NKx3.1 and FKBP5 detected by RT-qPCR.
CONCLUSIONS: EF2K and VPS34 inhibitors when combined with anti-androgens may solicit profound inhibitory effect on drugresistant CRPC cells. Molecular delineation demonstrated the direct target might be AR and its variants. These combinations offered a new therapeutic option for advanced PC treatments. (PCa) . miR-21 is among the most frequently deregulated miRs in cancer, and has been implicated in a castration-resistant prostate cancer (CRPC) phenotype. In addition to miR-21's many oncogenic effects, a positive feedback loop between miR-21 and the androgen receptor (AR) has been reported in PCa. Separately, miRs -221 and -222 have been shown to target tumor suppressor p27Kip1, leading to inhibition of apoptosis and aberrant proliferation. Nucleolin (NCL) is Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1111
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